Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor.

Humans CD28 Antigens Mesothelin Programmed Cell Death 1 Receptor / metabolism B7-H1 Antigen / genetics T-Lymphocytes / metabolism Mesothelioma Receptors, Antigen, T-Cell / metabolism Cytokines / metabolism
CD28 Mesothelin PD-1 PD-L1 Solid tumor T cell receptor fusion construct T cells

Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 04 05 2023
accepted: 26 09 2023
medline: 11 12 2023
pubmed: 18 10 2023
entrez: 17 10 2023
Statut: ppublish

Résumé

T cells expressing a mesothelin (MSLN)-specific T cell receptor fusion construct (TRuC

Identifiants

DOI: 10.1007/s00262-023-03556-7 PMID: 37848682 PMC: PMC10700406
pubmed: 37848682
doi: 10.1007/s00262-023-03556-7
pii: 10.1007/s00262-023-03556-7
pmc: PMC10700406
doi:

Substances chimiques

CD28 Antigens 0
Mesothelin J27WDC343N
Programmed Cell Death 1 Receptor 0
B7-H1 Antigen 0
Receptors, Antigen, T-Cell 0
Cytokines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4195-4207

Informations de copyright

© 2023. The Author(s).

Références

Immunity. 2016 May 17;44(5):973-88
pubmed: 27192564
Immunol Rev. 2009 May;229(1):114-25
pubmed: 19426218
Nat Biotechnol. 2002 Jan;20(1):70-5
pubmed: 11753365
Cancer Res. 2016 Mar 15;76(6):1578-90
pubmed: 26979791
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
Mol Immunol. 2012 Jul;51(3-4):263-72
pubmed: 22503210
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Cell Res. 2020 Aug;30(8):660-669
pubmed: 32467592
Front Immunol. 2022 Jul 13;13:953761
pubmed: 35911744
Elife. 2020 May 05;9:
pubmed: 32367803
J Immunol. 1989 Oct 15;143(8):2714-22
pubmed: 2794510
Mol Immunol. 2019 Oct;114:108-113
pubmed: 31351411
Cell Oncol (Dordr). 2023 Feb;46(1):227-235
pubmed: 36409438
Blood. 1990 Apr 1;75(7):1531-9
pubmed: 2156582
Immunol Rev. 2009 May;229(1):126-44
pubmed: 19426219
iScience. 2020 Apr 24;23(4):101023
pubmed: 32325413
Oncotarget. 2017 Apr 19;8(31):51936-51945
pubmed: 28881701
Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6575-9
pubmed: 1650475
Nat Rev Immunol. 2018 Aug;18(8):485-497
pubmed: 29789755
Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):E1594-603
pubmed: 25829543
Nature. 1993 Nov 4;366(6450):76-9
pubmed: 7694153
Immunol Rev. 2008 Aug;224:166-82
pubmed: 18759926
Front Immunol. 2020 Jul 16;11:1519
pubmed: 32765524
Oncoimmunology. 2023 Feb 24;12(1):2182058
pubmed: 36875551
Annu Rev Immunol. 2003;21:305-34
pubmed: 12471050
Clin Cancer Res. 2021 Jan 15;27(2):473-484
pubmed: 33028589
Ann Intern Med. 2022 Sep;175(9):1298-1304
pubmed: 36037471
J Immunol. 2013 Oct 15;191(8):4121-9
pubmed: 24026081
J Natl Cancer Inst. 2015 Jun 23;107(8):
pubmed: 26105028
J Clin Invest. 2016 Aug 1;126(8):3130-44
pubmed: 27454297
Immunotargets Ther. 2015 May 28;4:111-22
pubmed: 27471717
Cancer Res. 2017 Jul 1;77(13):3577-3590
pubmed: 28533272

Auteurs

Derrick McCarthy (D)

TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.

Michael Lofgren (M)

Adaptimmune, Philadelphia, PA, USA.

Amy Watt (A)

Adaptimmune, Philadelphia, PA, USA.

Holly Horton (H)

TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.

Philippe Kieffer-Kwon (P)

TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.

Jian Ding (J)

TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.

Sebastian Kobold (S)

Center of Integrated Protein Science Munich (CIPS‑M) and Division of Clinical Pharmacology, Department of Medicine IV, Member of the German Center for Lung Research (DZL), University Hospital, Ludwig-Maximilians-Universität, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.

Patrick A Baeuerle (PA)

TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.
Institute of Immunology, Ludwig-Maximilians-Universität, Munich, Germany.

Robert Hofmeister (R)

TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.

Dario A Gutierrez (DA)

TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.

Robert Tighe (R)

TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA. rob.tighe1973@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Functional enhancement of mesothelin-targeted...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Antigène CD28 › Functional enhancement of mesothelin-targeted...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes de surface › Mésothéline › Functional enhancement of mesothelin-targeted...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › Functional enhancement of mesothelin-targeted...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › Functional enhancement of mesothelin-targeted...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Functional enhancement of mesothelin-targeted...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs mésotheliales › Mésothéliome › Functional enhancement of mesothelin-targeted...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux antigènes › Récepteurs aux antigènes des cellules T › Functional enhancement of mesothelin-targeted...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Functional enhancement of mesothelin-targeted...